Ascendis Pharma A (ASND) Liabilities and Shareholders Equity (2012 - 2026)
Ascendis Pharma A's Liabilities and Shareholders Equity came in at $2.66 billion for the quarter ended Jun 30, 2026, up 115.8% from $1.23 billion a year earlier and up 13.3% from the prior quarter.
Powered by 
Analysis
Ascendis Pharma A (ASND) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
As of Dec 31, 2025, Ascendis Pharma A's Liabilities and Shareholders Equity was $1.47 billion, down 56.8% from the prior year.
- Liabilities and Shareholders Equity carries a five-year compound annual growth rate of -5.3% (years ended Dec 2020 to Dec 2025).
- Going back by year, Liabilities and Shareholders Equity was $3.4 billion in the year ended Dec 31, 2024 (+281.2%), $893.05 million in the year ended Dec 31, 2023 (-22.2%), $1.15 billion in the year ended Dec 31, 2022 (-49.8%) and $2.29 billion in the year ended Dec 31, 2021 (+18.6%).
- The figure for the quarter ended Jun 30, 2026 represents the highest quarterly Liabilities and Shareholders Equity since the quarter ended Dec 31, 2024.
- Year-over-year, Liabilities and Shareholders Equity increased in seven of the last eight quarters, with growth averaging 70.9%.
- The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in the quarter ended Dec 31, 2024 (growth of 278.4%), and the weakest in the quarter ended Dec 31, 2025 (a decline of 54.9%).
- Business Quant data shows ASND's Liabilities and Shareholders Equity at $2.35 billion (quarter ended Mar 31, 2026), $1.52 billion (quarter ended Dec 31, 2025) and $1.35 billion (quarter ended Sep 30, 2025) in the three quarters before the quarter ended Jun 30, 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 142.28 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 201.06 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 135.12 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 129.80 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 122.03 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 115.83 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 95.64 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 49.36 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 201.13 Bn |
| 10 | Ascendis Pharma A | 14.48 Bn | 10.74 Bn | 362.22 Mn | 2.61 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.61 Bn |
| Mar 31, 2026 | 2.30 Bn |
| Dec 31, 2025 | 1.53 Bn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 1.28 Bn |
| Mar 31, 2025 | 1.15 Bn |
| Dec 31, 2024 | 1.23 Bn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 812.02 Mn |
| Mar 31, 2024 | 866.26 Mn |
| Dec 31, 2023 | 913.78 Mn |
| Sep 30, 2023 | 922.33 Mn |
| Jun 30, 2023 | 895.33 Mn |
| Mar 31, 2023 | 1.05 Bn |
| Dec 31, 2022 | 1.16 Bn |
| Sep 30, 2022 | 1.25 Bn |
| Jun 30, 2022 | 1.39 Bn |
| Mar 31, 2022 | 1.54 Bn |
| Dec 31, 2021 | 1.23 Bn |
| Sep 30, 2021 | 1.40 Bn |
API Access
Ascendis Pharma A Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ASND&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "ASND", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ASND&period=max&api_key=YOUR_API_KEY");
const data = await res.json();